204 related articles for article (PubMed ID: 37696195)
1. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
Bourdakou MM; Fernández-Ginés R; Cuadrado A; Spyrou GM
Redox Biol; 2023 Nov; 67():102881. PubMed ID: 37696195
[TBL] [Abstract][Full Text] [Related]
2. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
3. Nrf2: a dark horse in Alzheimer's disease treatment.
Osama A; Zhang J; Yao J; Yao X; Fang J
Ageing Res Rev; 2020 Dec; 64():101206. PubMed ID: 33144124
[TBL] [Abstract][Full Text] [Related]
4. Brain Dicer1 Is Down-Regulated in a Mouse Model of Alzheimer's Disease Via Aβ42-Induced Repression of Nuclear Factor Erythroid 2-Related Factor 2.
Wang Y; Lian M; Zhou J; Wu S
Mol Neurobiol; 2020 Nov; 57(11):4417-4437. PubMed ID: 32737764
[TBL] [Abstract][Full Text] [Related]
5. Network-based stage-specific drug repurposing for Alzheimer's disease.
Savva K; Zachariou M; Bourdakou MM; Dietis N; Spyrou GM
Comput Struct Biotechnol J; 2022; 20():1427-1438. PubMed ID: 35386099
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease.
Qu Z; Sun J; Zhang W; Yu J; Zhuang C
Free Radic Biol Med; 2020 Nov; 159():87-102. PubMed ID: 32730855
[TBL] [Abstract][Full Text] [Related]
7. Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease.
Sharma V; Kaur A; Singh TG
Biomed Pharmacother; 2020 Sep; 129():110373. PubMed ID: 32603894
[TBL] [Abstract][Full Text] [Related]
8. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach.
Cuadrado A; Manda G; Hassan A; Alcaraz MJ; Barbas C; Daiber A; Ghezzi P; León R; López MG; Oliva B; Pajares M; Rojo AI; Robledinos-Antón N; Valverde AM; Guney E; Schmidt HHHW
Pharmacol Rev; 2018 Apr; 70(2):348-383. PubMed ID: 29507103
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.
Fragoulis A; Siegl S; Fendt M; Jansen S; Soppa U; Brandenburg LO; Pufe T; Weis J; Wruck CJ
Redox Biol; 2017 Aug; 12():843-853. PubMed ID: 28448946
[TBL] [Abstract][Full Text] [Related]
10. Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer's Disease.
Dalvi T; Dewangan B; Das R; Rani J; Shinde SD; Vhora N; Jain A; Sahu B
Cent Nerv Syst Agents Med Chem; 2020; 20(3):157-176. PubMed ID: 33087034
[TBL] [Abstract][Full Text] [Related]
11. Repurposed agents in the Alzheimer's disease drug development pipeline.
Bauzon J; Lee G; Cummings J
Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
[TBL] [Abstract][Full Text] [Related]
12. Articulating target-mining techniques to disinter Alzheimer's specific targets for drug repurposing.
G N S HS; Marise VLP; Rajalekshmi SG; Burri RR; Krishna Murthy TP
Comput Methods Programs Biomed; 2022 Jul; 222():106931. PubMed ID: 35724476
[TBL] [Abstract][Full Text] [Related]
13. Posttranscriptional regulation of Nrf2 through miRNAs and their role in Alzheimer's disease.
Kaundal RK; Datusalia AK; Sharma SS
Pharmacol Res; 2022 Jan; 175():106018. PubMed ID: 34863823
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer's Disease: Using the Multiomics Approach.
Advani D; Kumar P
ACS Omega; 2021 Jun; 6(21):13870-13887. PubMed ID: 34095679
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs.
Fagone P; Mangano K; Martino G; Quattropani MC; Pennisi M; Bella R; Fisicaro F; Nicoletti F; Petralia MC
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456509
[TBL] [Abstract][Full Text] [Related]
16. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes.
Wang Q; Li WX; Dai SX; Guo YC; Han FF; Zheng JJ; Li GH; Huang JF
J Alzheimers Dis; 2017; 56(4):1525-1539. PubMed ID: 28222515
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics methods in drug repurposing for Alzheimer's disease.
Siavelis JC; Bourdakou MM; Athanasiadis EI; Spyrou GM; Nikita KS
Brief Bioinform; 2016 Mar; 17(2):322-35. PubMed ID: 26197808
[TBL] [Abstract][Full Text] [Related]
19. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Approaches to Alzheimer's Disease Through Modulation of NRF2.
Bahn G; Jo DG
Neuromolecular Med; 2019 Mar; 21(1):1-11. PubMed ID: 30617737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
